vs
Insulet Corporation（PODD）与TRINET GROUP, INC.（TNET）财务数据对比。点击上方公司名可切换其他公司
TRINET GROUP, INC.的季度营收约是Insulet Corporation的1.6倍（$1.2B vs $783.7M），Insulet Corporation同比增速更快（31.2% vs -2.2%），Insulet Corporation自由现金流更多（$48.2M vs $43.0M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs -0.6%）
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
TriNet Group, Inc.是一家面向中小企业的专业雇主组织，总部位于加州都柏林，服务员工规模在3至2500人之间的各类机构。可提供薪资管理、健康福利管理服务，还能为客户提供劳动法规合规、风险降低相关咨询，可作为外包人力资源部门为企业分担人事相关事务。
PODD vs TNET — 直观对比
营收规模更大
TNET
是对方的1.6倍
$783.7M
营收增速更快
PODD
高出33.4%
-2.2%
自由现金流更多
PODD
多$5.2M
$43.0M
两年增速更快
PODD
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $783.7M | $1.2B |
| 净利润 | $101.6M | — |
| 毛利率 | 72.6% | — |
| 营业利润率 | 18.7% | 0.1% |
| 净利率 | 13.0% | — |
| 营收同比 | 31.2% | -2.2% |
| 净利润同比 | 0.9% | — |
| 每股收益（稀释后） | $1.42 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PODDTNET
| Q4 25 | $783.7M | $1.2B | ||
| Q3 25 | $706.3M | $1.2B | ||
| Q2 25 | $649.1M | $1.2B | ||
| Q1 25 | $569.0M | $1.3B | ||
| Q4 24 | $597.5M | $1.3B | ||
| Q3 24 | $543.9M | $1.2B | ||
| Q2 24 | $488.5M | $1.2B | ||
| Q1 24 | $441.7M | $1.3B |
净利润PODDTNET
| Q4 25 | $101.6M | — | ||
| Q3 25 | $87.6M | $34.0M | ||
| Q2 25 | $22.5M | $37.0M | ||
| Q1 25 | $35.4M | $85.0M | ||
| Q4 24 | $100.7M | — | ||
| Q3 24 | $77.5M | $45.0M | ||
| Q2 24 | $188.6M | $60.0M | ||
| Q1 24 | $51.5M | $91.0M |
毛利率PODDTNET
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — | ||
| Q1 24 | 69.5% | — |
营业利润率PODDTNET
| Q4 25 | 18.7% | 0.1% | ||
| Q3 25 | 16.7% | 4.1% | ||
| Q2 25 | 18.7% | 4.1% | ||
| Q1 25 | 15.6% | 8.9% | ||
| Q4 24 | 18.3% | -2.9% | ||
| Q3 24 | 16.2% | 4.7% | ||
| Q2 24 | 11.2% | 6.5% | ||
| Q1 24 | 12.9% | 9.7% |
净利率PODDTNET
| Q4 25 | 13.0% | — | ||
| Q3 25 | 12.4% | 2.8% | ||
| Q2 25 | 3.5% | 3.0% | ||
| Q1 25 | 6.2% | 6.6% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 14.2% | 3.6% | ||
| Q2 24 | 38.6% | 4.9% | ||
| Q1 24 | 11.7% | 7.2% |
每股收益（稀释后）PODDTNET
| Q4 25 | $1.42 | $0.02 | ||
| Q3 25 | $1.24 | $0.70 | ||
| Q2 25 | $0.32 | $0.77 | ||
| Q1 25 | $0.50 | $1.71 | ||
| Q4 24 | $1.38 | $-0.44 | ||
| Q3 24 | $1.08 | $0.89 | ||
| Q2 24 | $2.59 | $1.20 | ||
| Q1 24 | $0.73 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $287.0M |
| 总债务越低越好 | $930.8M | — |
| 股东权益账面价值 | $1.5B | $54.0M |
| 总资产 | $3.2B | $3.8B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资PODDTNET
| Q4 25 | — | $287.0M | ||
| Q3 25 | — | $321.0M | ||
| Q2 25 | — | $407.0M | ||
| Q1 25 | — | $349.0M | ||
| Q4 24 | — | $360.0M | ||
| Q3 24 | — | $301.0M | ||
| Q2 24 | — | $249.0M | ||
| Q1 24 | — | $383.0M |
总债务PODDTNET
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益PODDTNET
| Q4 25 | $1.5B | $54.0M | ||
| Q3 25 | $1.4B | $110.0M | ||
| Q2 25 | $1.5B | $107.0M | ||
| Q1 25 | $1.3B | $63.0M | ||
| Q4 24 | $1.2B | $69.0M | ||
| Q3 24 | $1.1B | $129.0M | ||
| Q2 24 | $998.4M | $100.0M | ||
| Q1 24 | $790.7M | $143.0M |
总资产PODDTNET
| Q4 25 | $3.2B | $3.8B | ||
| Q3 25 | $3.0B | $3.4B | ||
| Q2 25 | $3.5B | $3.7B | ||
| Q1 25 | $3.5B | $3.8B | ||
| Q4 24 | $3.1B | $4.1B | ||
| Q3 24 | $3.0B | $3.7B | ||
| Q2 24 | $2.9B | $3.7B | ||
| Q1 24 | $2.6B | $4.0B |
负债/权益比PODDTNET
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.72× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.3M | $61.0M |
| 自由现金流经营现金流 - 资本支出 | $48.2M | $43.0M |
| 自由现金流率自由现金流/营收 | 6.2% | 3.4% |
| 资本支出强度资本支出/营收 | 17.2% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.80× | — |
| 过去12个月自由现金流最近4个季度 | $377.7M | $234.0M |
8季度趋势，按日历期对齐
经营现金流PODDTNET
| Q4 25 | $183.3M | $61.0M | ||
| Q3 25 | $125.7M | $72.0M | ||
| Q2 25 | $196.5M | $75.0M | ||
| Q1 25 | $63.8M | $95.0M | ||
| Q4 24 | $147.7M | $65.0M | ||
| Q3 24 | $98.5M | $84.0M | ||
| Q2 24 | $96.5M | $39.0M | ||
| Q1 24 | $87.6M | $91.0M |
自由现金流PODDTNET
| Q4 25 | $48.2M | $43.0M | ||
| Q3 25 | $100.1M | $55.0M | ||
| Q2 25 | $177.9M | $57.0M | ||
| Q1 25 | $51.5M | $79.0M | ||
| Q4 24 | $94.1M | $47.0M | ||
| Q3 24 | $71.8M | $59.0M | ||
| Q2 24 | $74.0M | $22.0M | ||
| Q1 24 | $65.5M | $73.0M |
自由现金流率PODDTNET
| Q4 25 | 6.2% | 3.4% | ||
| Q3 25 | 14.2% | 4.5% | ||
| Q2 25 | 27.4% | 4.6% | ||
| Q1 25 | 9.1% | 6.1% | ||
| Q4 24 | 15.7% | 3.7% | ||
| Q3 24 | 13.2% | 4.8% | ||
| Q2 24 | 15.1% | 1.8% | ||
| Q1 24 | 14.8% | 5.8% |
资本支出强度PODDTNET
| Q4 25 | 17.2% | 1.4% | ||
| Q3 25 | 3.6% | 1.4% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 9.0% | 1.4% | ||
| Q3 24 | 4.9% | 2.0% | ||
| Q2 24 | 4.6% | 1.4% | ||
| Q1 24 | 5.0% | 1.4% |
现金转化率PODDTNET
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.43× | 2.12× | ||
| Q2 25 | 8.73× | 2.03× | ||
| Q1 25 | 1.80× | 1.12× | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | 1.87× | ||
| Q2 24 | 0.51× | 0.65× | ||
| Q1 24 | 1.70× | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
TNET
| Insurance Services | $1.1B | 85% |
| Professional Services | $169.0M | 14% |
